NEWS

Notizie dai Medici

PUBBLICAZIONE PUB MED :Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial – Giugno 2019

Support Care Cancer. 2019 Jun 17. doi: 10.1007/s00520-019-04881-3. [Epub ahead of print]

Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.

Author information

1Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA. cloprinzi@mayo.edu.
2Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.

Abstract

INTRODUCTION:

Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent clinical problem, with limited effective therapies. Preliminary non-randomized clinical trial data support that Scrambler Therapy is helpful in this situation.

METHODS:

Patients were eligible if they had CIPN symptoms for at least 3 months and CIPN-related tingling or pain at least 4/10 in severity during the week prior to registration. They were randomized to receive Scrambler Therapy versus transcutaneous electrical nerve stimulation (TENS) for 2 weeks. Patient-reported outcomes (PROs) were utilized to measure efficacy and toxicity daily for 2 weeks during therapy and then weekly for 8 additional weeks.

RESULTS:

This study accrued 50 patients, 25 to each of the 2 study arms; 46 patients were evaluable. There were twice as many Scrambler-treated patients who had at least a 50% documented improvement during the 2 treatment weeks, from their baseline pain, tingling, and numbness scores, when compared with the TENS-treated patients (from 36 to 56% compared with 16-28% for each symptom). Global Impression of Change scores for “neuropathy symptoms,” pain, and quality of life were similarly improved during the treatment weeks. Patients in the Scrambler group were more likely than those in the TENS group to recommend their treatment to other patients, during both the 2-week treatment period and the 8-week follow-up period (p < 0.0001). Minimal toxicity was observed.

CONCLUSIONS:

The results from this pilot trial were positive, supporting the conduct of further investigations regarding the use of Scrambler Therapy for treating CIPN.

KEYWORDS:

Chemotherapy-induced peripheral neuropathy; Scrambler; TENS

PMID:31209630
DOI:10.1007/s00520-019-04881-3
RICHIEDI L’ARTICOLO COMPLETO a info@lifeepistemeitlia.it

PUBBLICAZIONE PUB MED -Scrambler therapy for the treatment of diabetic peripheral neuropathy pain: A case report. Maggio 2019

Medicine (Baltimore). 2019 May;98(20):e15695. doi: 10.1097/MD.0000000000015695.

Scrambler therapy for the treatment of diabetic peripheral neuropathy pain: A case report.

Author information

1
Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Ewha Womans University Mokdong Hospital, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul, Republic of Korea.

Abstract

RATIONALE:

Neuropathy secondary to diabetes mellitus often does not respond well to conventional therapy. Scrambler therapy may be an alternative treatment for otherwise intractable neuropathy.

PATIENT CONCERNS:

A 45-year-old female complained of bilateral plantar foot pain. She had been treated for diabetes mellitus for 5 years. Oral analgesics did not resolve her pain. Even nerve block therapy did not adequately relieve her pain.

DIAGNOSES:

Diabetic peripheral neuropathy.

INTERVENTION:

Scrambler therapy.

OUTCOME:

Pain reduction; the treatment effect was based around the location of the scrambler patch.

LESSONS:

Scrambler therapy is effective for the treatment of diabetic peripheral neuropathy. Moreover, effective pain management can be achieved for patients who complain of general pain of the sole, including the toe, by attaching scrambler patches around the ankle.

PMID:31096512
DOI:10.1097/MD.0000000000015695
Richiedi l’articolo completo a info@lifeepeistemeitalia.it

PUBBLICAZIONE PUB MED Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis – Aprile 2019

Int J MS Care. 2019  Mar-Apr; 21(2): 76–80. doi: 10.7224/1537-2073.2017-083

PMCID: PMC6489430 PMID: 31049038

 

Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis

Maureen A. Mealy, RN, Scott D. Newsome, DO, Sharon L. Kozachik, PhD, RN, Michael Levy, MD, PhD, and Thomas J. Smith, MD

Corresponding author.

From the Department of Neurology (MAM, SDN, ML) and Department of Oncology (TJS), Johns Hopkins University School of Medicine, Baltimore, MD, USA; and Department of Acute and Chronic Care, Johns Hopkins University School of Nursing, Baltimore, MD, USA (MAM, SLK).

Correspondence: Thomas J. Smith, MD, Professor of Oncology and the Harry J. Duffey Family Professor of Palliative Medicine, Director of Palliative Medicine, Johns Hopkins Medical Institutions, Johns Hopkins Hospital, 600 N. Wolfe St., Blalock 369, Baltimore, MD 21287-0005, USA; e-mail: ude.imhj@631timst.

 

Abstract

Central neuropathic pain is a severely disabling consequence of conditions that cause tissue damage in the central nervous system. It is often refractory to treatments commonly used for peripheral neuropathy. Scrambler therapy is an emerging noninvasive pain-modifying technique that uses transcutaneous electrical stimulation of nociceptive fibers with the intent of reorganizing maladaptive signaling pathways. It has been examined for the treatment of peripheral neuropathy with favorable safety and efficacy outcomes, but its application to central neuropathic pain has not been reported in transverse myelitis. We describe the use of Scrambler therapy in a patient with persistent central neuropathic pain due to transverse myelitis. The patient had tried multiple drugs for treatment of the pain, but they were not effective or caused adverse effects. After a course of Scrambler therapy, pain scores improved considerably more than what was reported with previous pharmacologic and nonpharmacologic interventions. This case supports further investigation of Scrambler therapy in multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated disorders that damage the central nervous system.

 

Keywords: Autoimmune disease, Central pain, Demyelinating disease, Multiple sclerosis (MS), Neuropathic pain, Neuromodulation, Scrambler therapy, Transverse myelitis

Articolo completo su https://www.ncbi.nlm.nih.gov/pubmed/31049038

13 ottobre 2018 – Nuove prospettive nel trattamento del dolore e nelle cure palliative – Villafranca di Verona

13 ottobre  2018

Nuove prospettive nel trattamento del dolore e nelle cure palliative

Teatro Alida Ferrarini
Via Napoleone III
Villafranca di Verona

ore 10,00 – 10,30
La Scrambler Therapy: indicazioni ed efficacia
Dott.ssa Marianna Ricci

Iscrizioni all’indirizzo
info@unsorrisotralenuvole.org

Scarica il PROGRAMMA completo e il modulo di iscrizione: CORSO ECM pieghevole

 

29 settembre 2018 IL TRATTAMENTO DEL DOLORE CON APPROCCIO INTEGRATO- Genova

Con piacere annunciamo questo interessantissimo congresso ECM gratuito con iscrizione obbligatoria a Genova

29 settembre 2018

IL TRATTAMENTO DEL DOLORE CON APPROCCIO INTEGRATO

Hotel NH Collection Marina
Molo Ponte Calvi 5

 

RAZIONALE SCIENTIFICO

Il dolore è una patologia ad alto impatto sociale.
È causa di numerose giornate di lavoro perse ogni anno con notevole danno economico oltre che sanitario.
Ormai è largamente accettato che il fenomeno dolore sia multifattoriale: alterazioni anatomiche, neurofisiologiche, psicologiche e fattori sociali possono in varia misura influenzare l’espressione del dolore e renderlo differente da individuo a individuo.
Il paziente va considerato un unicum di corpo e mente e in questa visione olistica l’incontro vuole promuovere un approccio multidisciplinare mediante l’apporto di specialisti del settore, per portare a conoscenza le possibilità terapeutiche, sia farmacologiche, che fisiche che complementari.

 

PROGRAMMA SCIENTIFICO

08.00 Registrazione dei Partecipanti

08.30 Introduzione al Corso e Saluto delle Autorità

09.00 Lettura Il dolore: epifenomeno semplice dalla patogenesi complessa – M. Lacerenza (Milano)

 

I SESSIONE

Moderatori: P. Pelosi (Genova), A. Gratarola (Genova)

09.30 Terapia farmacologica: appropriatezza prescrittiva – S. Palermo (Genova)

10.00 Integratori: cosa c’è di concreto – L. Zappi (Genova)

10.30 Cannabis: mito o realtà – M. Bonfiglio (Lavagna)

11.00 Discussione

11.15 – 11.30 Coffee break

 

II SESSIONE

Moderatori: M. Bonfiglio (Lavagna), M. Tami (Genova)

11.30 La mindfullness-meditation – M. Lacerenza (Milano)

12.00 Epigenetica nutrizionale: ha un ruolo nel trattamento del dolore M. De Gregori (Pavia)

12.30 La Medicina Tradizionale Cinese nel trattamento del dolore:
ruolo dell’agopuntura, del Tuina e del QiGong – G. Vidili (Genova)

13.00 Discussione

 

13.30 – 14.30 Lunch

 

III SESSIONE

Moderatori: F. Ventura (Genova), L. Zappi (Genova)

14.30 Le terapie fisiche a confronto – G. Maggi (Genova)

15.00 La Scrambler Therapy – P. Brasesco (Genova)

15.30 Ozonoterapia: razionale e indicazioni – L. Valdenassi (Pavia)

16.00 Discussione

16.30 Conclusioni – L. Zappi (Genova)

17.00 Chiusura del Corso Questionario ECM online

ISCRIZIONE

La partecipazione al convegno è gratuita. Modalità di iscrizione online sul sito: www.symposiacongressi.com Sezione Eventi – La terapia del dolore con approccio integrato

SEGRETERIA ORGANIZZATIVA E PROVIDER ECM

Symposia Organizzazione Congressi Srl Provider accreditato Age.Na.S. N. 486 Piazza Campetto, 2/8 16123 Genova Tel: +39 010 255146 – Fax: +39 010 2770565 symposia@symposiacongressi.com www.symposiacongressi.com

locandina evento Genova 2018_pgr ok

Pagina 1 di 1112345...10...Ultima »